First-line therapy in HER2 positive metastatic breast cancer: is the mosaic fully completed or are we missing additional pieces?

The discovery of human epidermal growth factor receptor 2 (HER2) and its role in the biology of breast cancer and the subsequent development of HER2-targeted therapies, have dramatically improved clinical outcomes for women with early-stage and advanced HER2-positive breast cancer (BC). HER-2 target...

Descripción completa

Detalles Bibliográficos
Autores principales: Fabi, Alessandra, Malaguti, Paola, Vari, Sabrina, Cognetti, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4928292/
https://www.ncbi.nlm.nih.gov/pubmed/27357210
http://dx.doi.org/10.1186/s13046-016-0380-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4928292/
https://www.ncbi.nlm.nih.gov/pubmed/27357210
http://dx.doi.org/10.1186/s13046-016-0380-5

Ejemplares similares